ArticleAutoimmune diseases2012
Recombinant T-Cell Receptor Ligand (RTL) for Treatment of Multiple Sclerosis: A Double-Blind, Placebo-Controlled, Phase 1, Dose-Escalation Study.
Vijayshree Yadav et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
30 papers cite it
this paperpooled itcites it